Artículos de revistas
PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines
Fecha
2008-07Registro en:
García, Mariana Gabriela; Alaniz, Laura Daniela; Cordo Russo, Rosalia Ines; Alvarez, Elida Ester; Hajos, Silvia Elvira; PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines; Elsevier; Leukemia Research; 33; 2; 7-2008; 288-296
0145-2126
1873-5835
CONICET Digital
CONICET
Autor
García, Mariana Gabriela
Alaniz, Laura Daniela
Cordo Russo, Rosalia Ines
Alvarez, Elida Ester
Hajos, Silvia Elvira
Resumen
Upregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway has been described in some tumors related to multidrug resistance (MDR). The aim of this work was to analyze the relationship between PI3K/Akt, MDR and NF-kappaB in murine lymphoma cell lines resistant to vincristine (LBR-V160) and doxorubicin (LBR-D160) as well as in the sensitive line (LBR-). PI3K/Akt activity, analyzed by phosphatidylinositol trisphosphate production and phosphorylated Akt (p-Akt) expression, was higher in the resistant cell lines than in the sensitive one and inhibition with wortmannin or LY294002 improved apoptosis in the resistant cell lines. Vincristine but not doxorubicin increased p-Akt expression whereas co-treatment with PI3K inhibitors and vincristine increased apoptosis in the three cell lines. Wortmannin and LY294002 inhibited P-glycoprotein (Pgp) function and also increased NF-kappaB activity. We concluded that the PI3K/Akt pathway is involved in MDR in lymphoma cell lines and PI3K/Akt inhibition correlates down-regulation of NF-kappaB activity and inhibition Pgp function.